Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Phytother Res ; 35(6): 2997-3012, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-33368772

RESUMO

Sweet almond (Prunus dulcis (Mill.) D.A.Webb) is a known nut, which has long been used in several ethnomedical systems, especially in Persian medicine (PM) for its nutritional and therapeutic activities. In this study, we aimed to provide a summary on traditional uses, phytochemistry, and pharmacological activities of sweet almond. Thus, we reviewed textbooks of PM and electronic literature on traditional medicine. Moreover, the available data on the usage of sweet almond were searched in electronic databases to find articles on its pharmacological properties and phytochemistry. According to phytochemical investigations, this plant contains macronutrients, micronutrients, essential oils, various phenolic compounds, and phytosterols. Current pharmacological studies represent that Prunus dulcis has several biological activities including prebiotic, antimicrobial, antioxidant, antiinflammatory, anticancer, hepatoprotective, cardiometabolic protection, nootropic, anxiolytic, sedative-hypnotic, and nervous-improving effects. Further clinical trials and meta-analysis are required to draw a definitive conclusion on the efficacy and therapeutic activities of almond.


Assuntos
Medicina Tradicional , Nozes/química , Fitoterapia , Extratos Vegetais/farmacologia , Prunus dulcis/química , Animais , Anti-Infecciosos/farmacologia , Anti-Infecciosos/uso terapêutico , Anti-Inflamatórios/farmacologia , Anti-Inflamatórios/uso terapêutico , Antineoplásicos Fitogênicos/farmacologia , Antineoplásicos Fitogênicos/uso terapêutico , Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Suplementos Nutricionais/análise , Humanos , Sistema Nervoso/efeitos dos fármacos , Óleos Voláteis/farmacologia , Pérsia , Fenóis/farmacologia , Fenóis/uso terapêutico , Fitosteróis/farmacologia , Fitosteróis/uso terapêutico
2.
Int Immunopharmacol ; 89(Pt B): 107102, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33075713

RESUMO

Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patients with severe and critical COVID-19. Tocilizumab was added to the standard care of therapy at a dose of 324 mg (<100 kg bodyweight) or 486 mg (≥100 kg bodyweight). The study endpoints were all-cause mortality rate, changes in oxygen-support level, oxygen saturation, body temperature, respiratory rate, and laboratory variables during the study, and drug safety. Of 126 patients enrolled, 86 had severe and 40 had critical disease. Most patients were male (63.49%) and aged below 65 (78.57%). By day 14 of the study, 4.65% (4/86) of severe patients and 50.00% (20/40) of critical patients died. By the end, 6.98% (6/86) of severe patients and 60.00% (24/40) of critical patients died.Outcomes concerning three additional endpoints (oral temperature, oxygen saturation, and respiratory rate)were significantly improved as early as three days after tocilizumab administration in both groups of subjects, more considerably in severe patients. Significant improvement in the required level of oxygenation was reported in severe patients seven days after tocilizumab administration. No tocilizumab-related serious adverse event occurred in this study. Subcutaneous tocilizumab might improve some clinical parameters and reduce the risk of death in COVID-19 patients, particularly if used in the early stages of respiratory failure.


Assuntos
Anticorpos Monoclonais Humanizados/administração & dosagem , Tratamento Farmacológico da COVID-19 , SARS-CoV-2 , Adulto , Idoso , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados/efeitos adversos , COVID-19/mortalidade , Feminino , Humanos , Injeções Subcutâneas , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos
3.
J Med Microbiol ; 66(11): 1602-1606, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-29068280

RESUMO

INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal lung disease. One of the risk factors involved in the acquisition of IPF is viral infections, especially respiratory viruses. In the present study, we investigated the detection of respiratory viruses and the possible relationship between these viruses and IPF. METHODS: This cross-sectional study was supported by the Iran University of Medical Sciences (IUMS), Tehran, Iran. A total of 40 respiratory samples (five nasopharyngeal and 35 bronchoalveolar lavage specimens) were obtained from IPF patients referred to IUMS hospitals between April 2015 and December 2016. Assays were performed using the CLART Pneumovir DNA array assay, which made it possible to detect five genera of respiratory viruses simultaneously.Results/Key findings. Altogether, 22 of the 40 participants were male. Respiratory syncytial virus (RSV), parainfluenza, rhino, corona and influenza viruses were found in 2.5 % (1/40), 7.5 % (3/40), 10 % (4/40), 2.5 % (1/40) and 0% (0/40) of cases, respectively. CONCLUSION: Determining a correlation between the viruses and IPF is not an easy task, and therefore, this will require more research. In addition, the CLART Pneumovir DNA array can be considered as a useful method for simultaneous detection of several viral respiratory infections.


Assuntos
Fibrose Pulmonar Idiopática/virologia , Viroses/complicações , Idoso , Líquido da Lavagem Broncoalveolar/virologia , Estudos Transversais , DNA Viral/isolamento & purificação , Feminino , Humanos , Fibrose Pulmonar Idiopática/epidemiologia , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Nasofaringe/virologia , Viroses/epidemiologia
4.
Microb Pathog ; 104: 171-174, 2017 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-28115263

RESUMO

AIM OF THE STUDY: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, which can be lethal with chronic complications. Viral infections may be associated with IPF and other fibrotic lung diseases. In the present study, we investigate for the first time in Iran the related viral etiology of IPF in order to detect three respiratory viruses; human adenovirus, enterovirus and bocavirus. MATERIALS AND METHODS: In this cross-sectional study which was supported by Iran University of Medical Sciences, Tehran, Iran. The diagnostic criteria for IPF were based on internationally accepted clinical and imaging criteria in accordance with the 2011 IPF guidelines. 30 nasopharyngeal (NP) swabs or broncho-alveolar lavage (BAL) samples were obtained from the lung of IPF patients that were diagnosed by a sophisticated practitioner from April 2015 to February 2016. Real-time (RT) polymerase chain reaction (PCR) method was performed to detect the three viruses. Fluorescence dye of a labeled probe recorded the results in order to create positive and negative controls. SPSS version 20 software was used to calculate basic descriptive and frequency features. RESULTS: Of 30 specimens, 13 (43.4%) were male and 17 (56.6%) were female with the total mean age ± standard deviation 68.2 ± 12.0. RT-PCR assay results illustrated there was no infection of human adenovirus, enterovirus, and bocavirus detected in these samples. Significant results between IPF incidence and variables were not significant (p > 0.05). CONCLUSION: The causes of IPF in Iranian patients need more research although, based on the results of this study, there was no association between human adenovirus, enterovirus, bocavirus, and IPF.


Assuntos
Adenovírus Humanos/isolamento & purificação , Bocavirus/isolamento & purificação , Enterovirus/isolamento & purificação , Fibrose Pulmonar Idiopática/virologia , Viroses/diagnóstico , Idoso , Idoso de 80 Anos ou mais , Líquido da Lavagem Broncoalveolar/virologia , Estudos Transversais , Feminino , Humanos , Fibrose Pulmonar Idiopática/etiologia , Irã (Geográfico)/epidemiologia , Masculino , Pessoa de Meia-Idade , Nasofaringe/virologia , Reação em Cadeia da Polimerase em Tempo Real , Viroses/virologia
5.
Biomed Pharmacother ; 81: 329-336, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27261610

RESUMO

BACKGROUND: Pulmonary fibrosis induced by paraquat (PQ) has caused a large number of human fatalities all over the world, especially in Asian region. The main potential mechanism of PQ toxicity has been thought to be mediated by ROS. The present study was designed to evaluate the efficacy of the Berberis vulgaris fruit extract (BVFE) against PQ-induced pulmonary fibrosis in rats. METHODS: Forty male rats were randomly divided into five experimental groups each containing eight rats. Groups 1 and 2, served as a negative and positive control and received a single dose of intratracheal instillation of saline and PQ (20mg/kg), respectively. Groups 3-5 were treated with different doses of BVFE (100, 200, 400mg/kg/day, orally) 1 week before the PQ injection and continued for 3 weeks. The rats were sacrificed 21days after PQ. Malondialdehyde (MDA), Hydroxyproline, inflammatory and fibrogenic cytokine tumor necrosis factor (TNF)-α, interleukin (IL)-6 and transforming growth factor (TGF)-ß1 in lung tissue were determined. Presence of fibrosis, inflammatory cells, connective tissue and collagen deposition in lung were evaluated microscopically by hematoxylin and eosin (H&E) staining. Dried extract was standardized by amount of berberine by HPTLC methods by silica gel plate. RESULTS: The results showed that PQ could significantly increase the lung MDA, hydroxyproline, TNF-α, IL-6 and TGF-ß1 levels. BVFE ameliorated the biochemical and histological lung alterations induced by PQ. CONCLUSIONS: The present study indicates the hydroalcolic extract of Berberis vulgaris fruit has beneficial effects in rat pulmonary fibrosis induced by PQ in a dose-dependent manner, possibly by anti-oxidant and anti- inflammatory properties, which might be due to its berberine alkaloid content.


Assuntos
Berberis/química , Frutas/química , Paraquat/toxicidade , Extratos Vegetais/uso terapêutico , Substâncias Protetoras/uso terapêutico , Fibrose Pulmonar/tratamento farmacológico , Animais , Cromatografia em Camada Fina , Hidroxiprolina/metabolismo , Mediadores da Inflamação/metabolismo , Interleucina-6/metabolismo , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Pulmão/patologia , Masculino , Malondialdeído/metabolismo , Extratos Vegetais/farmacologia , Substâncias Protetoras/farmacologia , Fibrose Pulmonar/patologia , Ratos Sprague-Dawley , Fator de Crescimento Transformador beta1/metabolismo , Fator de Necrose Tumoral alfa/metabolismo
6.
Iran J Neurol ; 13(3): 131-7, 2014 Jul 04.
Artigo em Inglês | MEDLINE | ID: mdl-25422731

RESUMO

BACKGROUND: The rapidity of progression of amyotrophic lateral sclerosis (ALS) to death or respiratory failure impacts patients, clinicians, and clinical investigators. The aim of this study is to evaluate of the pulmonary function tests (PFTs) in patients with ALS and the association between these PFTs and survival Methods: A total of 36 ALS patients who PFTs, including vital capacity (VC), maximum mid-expiratory flow rate (MMEFR), forced vital capacity (FVC), and forced expiratory volume in 1 s (FEV1), were available from the time of diagnosis were included in this study. Non-pulmonary characteristics assessed at the time of PFTs. Data were analyzed using chi-square, Student's independent t-test, Kaplan-Meier, correlation, and receiver operating characteristic (ROC) curve. RESULTS: The mean age of subjects was 55.36 (SD = 12.24) year, and the male to female ratio was 2.6. Twenty-five (69.4%) were died in 5 years period of our study. The mean and median survival time (In months) was calculated as 42.51 (95% confidence interval [CI] 33.64-51.39) and 38 (95% CI 27.23-48.77) months, respectively. The rate of ALS survival was 74% at 1(st) year, 41% at 3(rd) year and 10% at 5(th) year of starting symptoms. The results of Kaplan-Meier test showed survival was significantly longer in the group with PFTs closer to normal. In addition, ROC analysis showed that FVC < 50% could potentially be a predictor of death in ALS patients(P = 0.003, area under curve = 0.649). CONCLUSION: We found single measures of upright FVC, FEV1 to be significantly associated with survival, even after controlling for relevant non-pulmonary patient characteristics. Our study demonstrated that upright FVC, FEV1, VC, and MMEFR are useful non-invasive measures in the prediction of survival in ALS.

7.
Ann Allergy Asthma Immunol ; 113(4): 404-9, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25091714

RESUMO

BACKGROUND: Vitamin D is hypothesized to have some roles in innate and adaptive immunity, inflammation reduction, and remodeling; therefore, it is supposed to affect the asthma phenotype, severity, and response to inhaled corticosteroid (ICS). OBJECTIVE: To explore the synergistic effects of vitamin D supplementation in addition to asthma controllers (ICS or ICS plus long-acting ß-agonist) on airway functions. METHODS: A randomized clinical trial was conducted in 130 individuals aged 10 to 50 years who lived in Tehran during a 24-week period. Data on age, sex, body mass index, stage of asthma, serum total IgE, history of allergic rhinitis, atopic dermatitis, food allergy, and urticaria were collected. Spirometric parameters (forced expiratory volume in 1 second [FEV1] and ratio of FEV1 to forced vital capacity) and serum vitamin D measurement were obtained before and 8 and 24 weeks after the intervention. Patients were divided in 2 groups randomly. Both groups received asthma controllers (budesonide or budesonide plus formoterol) according to their stage, but the intervention group received vitamin D supplementation (100,000-U bolus intramuscularly plus 50,000 U orally weekly) in addition to asthma controllers. RESULTS: FEV1 improved significantly in both groups after 8 weeks, but no significant difference was found between the 2 groups at baseline (P = .20) or after 8 weeks (P = .99); however, a significant improvement was seen in the intervention group in the last 16 weeks, and FEV1 was significantly better in the intervention group than the other group after 24 weeks (P < .001). CONCLUSION: Vitamin D supplementation associated with asthma controllers could significantly improve FEV1 in mild to moderate persistent asthma after 24 weeks. TRIAL REGISTRATION: irct.ir Identifier: IRCT201302079608N1.


Assuntos
Asma/tratamento farmacológico , Budesonida/uso terapêutico , Suplementos Nutricionais , Etanolaminas/uso terapêutico , Vitamina D/uso terapêutico , Adolescente , Adulto , Anti-Inflamatórios/uso terapêutico , Broncodilatadores/uso terapêutico , Criança , Dermatite Atópica/complicações , Sinergismo Farmacológico , Feminino , Hipersensibilidade Alimentar/complicações , Volume Expiratório Forçado , Fumarato de Formoterol , Humanos , Imunoglobulina E/sangue , Irã (Geográfico) , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Rinite Alérgica/complicações , Urticária/complicações , Capacidade Vital , Vitamina D/sangue , Adulto Jovem
8.
Arch Environ Occup Health ; 67(2): 98-102, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22524650

RESUMO

In developing countries, musculoskeletal complaints are considered as main cause of occupational complications and disability. Economic burden of these complications more than workers has impact on organization and society in general. In Iranian aluminum industries, workers are directly involved in production process and physical activities such as manual material handling and awkward postures are very common. The present study was performed for assessment of musculoskeletal complaints prevalence among workers of Iranian aluminum industries. Participants in this cross-sectional study were 493 workers of 3 Iranian aluminum industries with random selection. Data of musculoskeletal complaints were gathered by means of the standardized Nordic self-reporting questionnaire. Demographic and work-related data were collected into the checklist. Findings of this study showed that 65.5% of workers in past week and 77.5% of workers in past year had claimed one of the musculoskeletal complaints in their work places. Lumbar, knee(s), and upper back had the most musculoskeletal complaints prevalence in participants. Musculoskeletal complaints in past week and year had significant association with job duration and age in these workers. Musculoskeletal complaints in Iranian aluminum industries happened in high rate. Ergonomic intervention strategies in the workplaces must be the focus for elimination of environmental hazards such as apposition on the time of work and manual handling of heavy loads.


Assuntos
Alumínio/efeitos adversos , Indústrias/estatística & dados numéricos , Doenças Musculoesqueléticas/epidemiologia , Doenças Profissionais/epidemiologia , Adulto , Idoso , Dor nas Costas/epidemiologia , Estudos Transversais , Feminino , Humanos , Irã (Geográfico) , Traumatismos do Joelho/epidemiologia , Masculino , Pessoa de Meia-Idade , Prevalência , Inquéritos e Questionários , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA